T richoderma  species fungemia after high‐dose chemotherapy and autologous stem cell transplantation: a case report | Zendy

Festuccia M. | Zendy; Giaccone L. | Zendy; Gay F. | Zendy; Brunello L. | Zendy; Maffini E. | Zendy; Ferrando F. | Zendy; Talamo E. | Zendy; Boccadoro M. | Zendy; Serra R. | Zendy; Barbui A. | Zendy; Bruno B. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

T richoderma species fungemia after high‐dose chemotherapy and autologous stem cell transplantation: a case report

Author(s) -

Festuccia M.,

Giaccone L.,

Gay F.,

Brunello L.,

Maffini E.,

Ferrando F.,

Talamo E.,

Boccadoro M.,

Serra R.,

Barbui A.,

Bruno B.

Publication year - 2014

Publication title -

transplant infectious disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.69

H-Index - 67

eISSN - 1399-3062

pISSN - 1398-2273

DOI - 10.1111/tid.12245

Subject(s) - fungemia , medicine , voriconazole , hematopoietic stem cell transplantation , multiple myeloma , melphalan , autologous stem cell transplantation , transplantation , stem cell , chemotherapy , surgery , oncology , mycosis , dermatology , antifungal , biology , genetics

We present a case of T richoderma fungemia with pulmonary involvement in a multiple myeloma patient, who was severely immunocompromised and heavily treated with high‐dose melphalan, and underwent autologous hematopoietic cell transplantation. This is the first report, to our knowledge, of proven T richoderma fungemia, defined by published criteria, successfully treated with voriconazole.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research